Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Allergy, Asthma & Clinical Immunology
Published in: Allergy, Asthma & Clinical Immunology 2/2014

Open Access 01-12-2014 | Meeting abstract

A pilot study of quality of life, mood, sleepiness and fatigue in patients with primary humoral immunodeficiency transitioning to subcutaneous immunoglobulin therapy

Authors: Persia Pourshahnazari, Gina Tsai, Adriana Martin, Amin Kanani, Donald Stark, R Robert Schellenberg

Published in: Allergy, Asthma & Clinical Immunology | Special Issue 2/2014

Login to get access

Excerpt

Immunoglobulin replacement therapy is standard of care for patients with primary humoral immunodeficiency [1]. Compared with intravenous immunoglobulin (IVIG), subcutaneous immunoglobulin (SCIG) offers comparable efficacy, lower costs and reduced systemic reactions [2, 3]. However, little is known about effects on quality of life when patients transition from IVIG to SCIG. It was our objective to assess changes in quality of life, mood, sleepiness and fatigue in patients transitioning from IVIG to SCIG. …
Literature
1.
Chapel HM: Consensus panel for the diagnosis and management of primary antibody deficiencies: consensus on diagnosis and management of primary antibody deficiencies. Br Med J. 1994, 308: 581-585. 10.1136/bmj.308.6928.581.CrossRef
2.
Abolhassani H, Sadaghiani MS, Aghamohammadi A, Ochs HD, Rezaei N: Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis. J Clin Immunol. 2012, 32 (6): 1180-92. 10.1007/s10875-012-9720-1.CrossRefPubMed
3.
Ho C, Membe S, Cimon K, Roifman C, Kanani A, Morrison A: Subcutaneous versus intravenous immunoglobulin for primary immunodeficiencies: systematic review and economic evaluation. Technology report number 98. 2008, Ottawa: Canadian Agency for Drugs and Technologies in Health
Metadata
Title
A pilot study of quality of life, mood, sleepiness and fatigue in patients with primary humoral immunodeficiency transitioning to subcutaneous immunoglobulin therapy
Authors
Persia Pourshahnazari
Gina Tsai
Adriana Martin
Amin Kanani
Donald Stark
R Robert Schellenberg
Publication date
01-12-2014
Publisher
BioMed Central
DOI
https://doi.org/10.1186/1710-1492-10-S2-A37

Other articles of this Special Issue 2/2014

Allergy, Asthma & Clinical Immunology 2/2014 Go to the issue

Meeting abstract

Omalizumab treatment of moderate to severe asthma in the adolescent and pediatric population

Meeting abstract

Efficacy and safety of MK-7243: a grass allergy sublingual immunotherapy tablet evaluated in Canadian adults and children

Meeting abstract

Tiotropium respimat® add-on therapy reduces airflow obstruction in patients with symptomatic moderate asthma, independent of TH2 inflammatory status

Meeting abstract

C-CARE: comparing three years of anaphylaxis in children treated at the Montreal Children’s Hospital

Meeting abstract

IL-4 and IL-13 regulate TLR expression and eosinophil-basophil differentiation of cord blood CD34+ progenitor cells

Meeting abstract

Acute generalized exanthematous pustulosis from imatinib